C. Mitsiades

发表

Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-β inhibitors

N. Munshi, P. Richardson, Shaji K. Kumar, 2005, Oncogene.

Shock Protein 90 Inhibition on Dendritic Cell Phenotypic and Functional Effects of Heat

N. Munshi, R. Batchu, Y. Tai, 2007 .

Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.

N. Munshi, P. Richardson, Shaji K. Kumar, 2009, Cancer cell.

Immmunomodulatory Drug (Revamid) Co-stimulates T cells via The B7-CD28 pathway

N. Munshi, P. Richardson, N. Mitsiades, 2003 .

Bortezomib induces canonical nuclear factor- (cid:1) B activation in multiple myeloma cells

N. Munshi, P. Richardson, D. Chauhan, 2009 .

Modulation of Signaling Cascades by Inhibitors of Histone Deacetylase and Akt

N. Munshi, J. Bradner, P. Richardson, 2009 .

MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.

N. Munshi, L. Dang, P. Richardson, 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies

N. Mitsiades, S. Treon, R. Schlossman, 2001, Journal of immunotherapy.

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism.

K. Anderson, S. Verselis, E. Fox, 2007, Blood.

Targeting the β-catenin/TCF transcriptional complex in the treatment of multiple myeloma

D. Carrasco, Yunyu Zhang, K. Sukhdeo, 2007, Proceedings of the National Academy of Sciences.

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma.

N. Munshi, P. Tassone, D. Chauhan, 2007, Blood.

Gene expression analysis of B‐lymphoma cells resistant and sensitive to bortezomib *

K. Anderson, N. Munshi, H. Ploegh, 2006, British journal of haematology.

MUC1-C is a master regulator of MICA/B NKG2D ligand and exosome secretion in human cancer cells

D. Kufe, R. Ahmad, Atsushi Fushimi, 2023, Journal for ImmunoTherapy of Cancer.

Insulin-like Growth Factor I and Urokinase-type Plasminogen Activator Bioregulation System as a Survival Mechanism of Prostate Cancer Cells in Osteoblastic Metastases: Development of Anti-Survival Factor Therapy for Hormone-Refractory Prostate Cancer

C. Mitsiades, M. Koutsilieris, A. Sourla, 2000, Molecular medicine.

Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies.

N. Mitsiades, S. Treon, R. Schlossman, 2001, Journal of immunotherapy : official journal of the Society for Biological Therapy.

Monoclonal Antibody–Based Therapies in Human Multiple Myeloma

N. Munshi, P. Richardson, P. Tassone, 2009 .

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2008 .

beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells.

N. Munshi, N. Mitsiades, D. Chauhan, 2002, Experimental hematology.

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells

Constantine Mitsiades, P. Richardson, D. Chauhan, 2004, Oncogene.

P38 MAPK Inhibition Enhances PS-341 (bortezomib)-Induced Cytotoxicity Against Multiple Myeloma Cells.

Kenneth C. Anderson, Paul G. Richardson, Nikhil C. Munshi, 2004 .

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy

J. Laubach, P. Richardson, T. Hideshima, 2009 .